381 related articles for article (PubMed ID: 25301686)
1. Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer.
Del Bufalo D; Desideri M; De Luca T; Di Martile M; Gabellini C; Monica V; Busso S; Eramo A; De Maria R; Milella M; Trisciuoglio D
Mol Cancer; 2014 Oct; 13():230. PubMed ID: 25301686
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer.
Kawabata S; Chiang CT; Tsurutani J; Shiga H; Arwood ML; Komiya T; Gills JJ; Memmott RM; Dennis PA
Oncotarget; 2014 Feb; 5(4):1062-70. PubMed ID: 24658085
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer.
Markova B; Hähnel PS; Kasper S; Herbertz S; Schuler M; Breitenbuecher F
J Cancer Res Clin Oncol; 2012 Apr; 138(4):545-54. PubMed ID: 22203472
[TBL] [Abstract][Full Text] [Related]
5. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
Takezawa K; Okamoto I; Tanizaki J; Kuwata K; Yamaguchi H; Fukuoka M; Nishio K; Nakagawa K
Mol Cancer Ther; 2010 Jun; 9(6):1647-56. PubMed ID: 20530710
[TBL] [Abstract][Full Text] [Related]
6. Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer.
Ceppi P; Rapa I; Lo Iacono M; Righi L; Giorcelli J; Pautasso M; Billè A; Ardissone F; Papotti M; Scagliotti GV
Int J Cancer; 2012 Apr; 130(8):1777-86. PubMed ID: 21618517
[TBL] [Abstract][Full Text] [Related]
7. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer.
Takezawa K; Okamoto I; Okamoto W; Takeda M; Sakai K; Tsukioka S; Kuwata K; Yamaguchi H; Nishio K; Nakagawa K
Br J Cancer; 2011 May; 104(10):1594-601. PubMed ID: 21487406
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of dUTPase induces synthetic lethality with thymidylate synthase-targeted therapies in non-small cell lung cancer.
Wilson PM; LaBonte MJ; Lenz HJ; Mack PC; Ladner RD
Mol Cancer Ther; 2012 Mar; 11(3):616-28. PubMed ID: 22172489
[TBL] [Abstract][Full Text] [Related]
9. Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines.
Nagai S; Takenaka K; Sonobe M; Wada H; Tanaka F
Chemotherapy; 2008; 54(3):166-75. PubMed ID: 18560222
[TBL] [Abstract][Full Text] [Related]
10. Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells.
Tekle C; Giovannetti E; Sigmond J; Graff JR; Smid K; Peters GJ
Br J Cancer; 2008 Sep; 99(5):750-9. PubMed ID: 18728666
[TBL] [Abstract][Full Text] [Related]
11. HDAC inhibitor ITF2357 reduces resistance of mutant-KRAS non-small cell lung cancer to pemetrexed through a HDAC2/miR-130a-3p-dependent mechanism.
Cui J; Xu F; Bai W; Zhao T; Hong J; Zuo W
J Transl Med; 2023 Feb; 21(1):125. PubMed ID: 36793108
[TBL] [Abstract][Full Text] [Related]
12. Astaxanthin enhances pemetrexed-induced cytotoxicity by downregulation of thymidylate synthase expression in human lung cancer cells.
Liao KS; Wei CL; Chen JC; Zheng HY; Chen WC; Wu CH; Wang TJ; Peng YS; Chang PY; Lin YW
Regul Toxicol Pharmacol; 2016 Nov; 81():353-361. PubMed ID: 27693704
[TBL] [Abstract][Full Text] [Related]
13. Pemetrexed downregulates ERCC1 expression and enhances cytotoxicity effected by resveratrol in human nonsmall cell lung cancer cells.
Chen RS; Ko JC; Chiu HC; Wo TY; Huang YJ; Tseng SC; Chen HJ; Huang YC; Jian YJ; Lee WT; Lin YW
Naunyn Schmiedebergs Arch Pharmacol; 2013 Dec; 386(12):1047-59. PubMed ID: 23912706
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells.
Tung CL; Chiu HC; Jian YJ; Jian YT; Chen CY; Syu JJ; Wo TY; Huang YJ; Tseng SC; Lin YW
Exp Cell Res; 2014 Apr; 322(2):345-54. PubMed ID: 24530475
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma.
Marampon F; Leoni F; Mancini A; Pietrantoni I; Codenotti S; Ferella L; Megiorni F; Porro G; Galbiati E; Pozzi P; Mascagni P; Budillon A; Maggio R; Tombolini V; Fanzani A; Gravina GL; Festuccia C
J Cancer Res Clin Oncol; 2019 Feb; 145(2):393-409. PubMed ID: 30474756
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of autophagy potentiates pemetrexed and simvastatin-induced apoptotic cell death in malignant mesothelioma and non-small cell lung cancer cells.
Hwang KE; Kim YS; Jung JW; Kwon SJ; Park DS; Cha BK; Oh SH; Yoon KH; Jeong ET; Kim HR
Oncotarget; 2015 Oct; 6(30):29482-96. PubMed ID: 26334320
[TBL] [Abstract][Full Text] [Related]
17. Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells.
Wu MF; Hsiao YM; Huang CF; Huang YH; Yang WJ; Chan HW; Chang JT; Ko JL
J Thorac Oncol; 2010 Aug; 5(8):1143-51. PubMed ID: 20559153
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression.
Noro R; Miyanaga A; Minegishi Y; Okano T; Seike M; Soeno C; Kataoka K; Matsuda K; Yoshimura A; Gemma A
Cancer Sci; 2010 Jun; 101(6):1424-30. PubMed ID: 20384633
[TBL] [Abstract][Full Text] [Related]
19. Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography.
Frings V; van der Veldt AA; Boellaard R; Herder GJ; Giovannetti E; Honeywell R; Peters GJ; Thunnissen E; Hoekstra OS; Smit EF
PLoS One; 2013; 8(5):e63705. PubMed ID: 23717468
[TBL] [Abstract][Full Text] [Related]
20. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells.
Li T; Ling YH; Goldman ID; Perez-Soler R
Clin Cancer Res; 2007 Jun; 13(11):3413-22. PubMed ID: 17545550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
